![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Guerbet SA | EU:GBT | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.80 | 37.25 | 42.00 | 0.00 | 06:30:05 |
Consolidated Group revenue (IFRS)
In millions of euros | 9 months 2015 | 9 months 2014 | Change | Q3 2015 | Q3 2014 | Change |
Sales in Europe | 236.7 | 214.9 | 10.1% | 78.0 | 70.9 | 9.9% |
Sales in Other Markets | 106.9 | 87.6 | 22.1% | 38.3 | 29.0 | 32.5% |
Total | 343.6 | 302.5 | 13.6% | 116.3 | 99.9 | 16.5% |
Double-digit growth in business activity in Europe and in Other MarketsThird-quarter sales in Europe were €78 million, with growth of 9.9% at current exchange rates, for total sales of €236.7 million in the first nine months of the year. This growth in performance is once again primarily explained by contributions from Germany, the United Kingdom, Turkey, and Switzerland. At constant exchange rates, growth was 8.3% over the quarter.
For Other Markets, continued higher sales in the United States make up most of the quarter's growth. Revenue from this part of the world totalled €38.3 million, an increase of 32.5% for the quarter. This includes €0.7 million in positive exchange rate effects.
Good performance from Xenetix® and Dotarem® Sales from the MRI segment came to €53.8 million over the quarter, for growth of 28.1% compared to the 3rd quarter of 2014. Sales of Dotarem contributed strongly to revenue, with the rising success of Dotarem on the American market and continued strong sales in Germany.
The X-Ray segment posted quarterly revenue of €46.1 million. Sales benefited from a highly favourable volume effect from Xenetix. At the end of September, cumulative X-Ray revenue was €144.2 million (+2.8%).
Sales performance of Lipiodol® and Patent Blue V has supported growth in the IRT segment of more than 40% over the past nine months.
The Imaging Solutions and Services (ISS) segment saw cumulative growth of 6.9%, for sales of €13.5 million.
Meeting annual objectivesAcquisition of Mallinckrodt's CMDS activity should become final in the coming weeks, pending approval of the transaction by the relevant oversight authorities.
Following this successful third quarter, Guerbet confirms its revenue objective, not counting acquisitions, of €445 million (+/- 2%) and its current operating margin objective excluding acquisition-related costs (operating income/net sales) of 11% (+/- 1 point).
Upcoming events:
About Guerbet
Guerbet is a pioneer in the contrast agent field, with nearly 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B - Mid Caps) and generated revenue of €409 million in 2014. It had a total workforce of 1,461 employees at 31 December 2014.
For more information about Guerbet, please go to www.guerbet.com
Contacts
Guerbet | Actifin |
Jean-François Le MartretChief Financial Officer+33 (0)1 45 91 50 00 | Christophe de Lylle / Benjamin Lehari+33 (0)1 56 88 11 11cdelylle@actifin.fr / blehari@actifin.fr PressJennifer Jullia+33 (0)1 56 88 11 19jjullia@actifin.fr |
Press release http://hugin.info/159769/R/1960884/714918.pdf
HUG#1960884
1 Year Guerbet Chart |
1 Month Guerbet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions